» Articles » PMID: 30563034

A Wake-Up Call: We Need Phage Therapy Now

Overview
Journal Viruses
Publisher MDPI
Specialty Microbiology
Date 2018 Dec 20
PMID 30563034
Citations 55
Authors
Affiliations
Soon will be listed here.
Abstract

The rise of multidrug-resistant bacteria has resulted in an increased interest in phage therapy, which historically preceded antibiotic treatment against bacterial infections. To date, there have been no reports of serious adverse events caused by phages. They have been successfully used to cure human diseases in Eastern Europe for many decades. More recently, clinical trials and case reports for a variety of indications have shown promising results. However, major hurdles to the introduction of phage therapy in the Western world are the regulatory and legal frameworks. Present regulations may take a decade or longer to be fulfilled. It is of urgent need to speed up the availability of phage therapy.

Citing Articles

Isolation and characterization of new lytic bacteriophage PSA-KC1 against Pseudomonas aeruginosa isolates from cystic fibrosis patients.

Can Kurt K, Kurt H, Tokuc E, Ozbey D, Arabaci D, Aydin S Sci Rep. 2025; 15(1):6551.

PMID: 39994360 PMC: 11850609. DOI: 10.1038/s41598-025-91073-1.


Synergistic effects of zP-1 phage and ampicillin against methicillin-resistant Staphylococcus aureus isolated from hospital staff.

Mehmood Z, Kanwar R, Ullah K, Ali S, Aslam M, Qadeer A Ir J Med Sci. 2025; .

PMID: 39912979 DOI: 10.1007/s11845-025-03898-4.


Phage-induced disturbance of a marine sponge microbiome.

Steiner L, Schmittmann L, Rahn T, Lachnit T, Jahn M, Hentschel U Environ Microbiome. 2024; 19(1):97.

PMID: 39593141 PMC: 11590407. DOI: 10.1186/s40793-024-00637-7.


Optimization of bacteriophage therapy for difficult-to-treat musculoskeletal infections: a bench-to-bedside perspective.

Bessems L, Chen B, Uyttebroek S, Devolder D, Lood C, Verwimp S Front Cell Infect Microbiol. 2024; 14:1434397.

PMID: 39290977 PMC: 11405300. DOI: 10.3389/fcimb.2024.1434397.


An enterococcal phage protein inhibits type IV restriction enzymes involved in antiphage defense.

Bullen N, Johnson C, Andersen S, Arya G, Marotta S, Lee Y Nat Commun. 2024; 15(1):6955.

PMID: 39138193 PMC: 11322646. DOI: 10.1038/s41467-024-51346-1.


References
1.
Sabitova Y, Fomenko N, Tikunov A, Stronin O, Khasnatinov M, Abmed D . Multilocus sequence analysis of Borrelia burgdorferi sensu lato isolates from Western Siberia, Russia and Northern Mongolia. Infect Genet Evol. 2018; 62:160-169. DOI: 10.1016/j.meegid.2018.04.015. View

2.
Kutateladze M, Adamia R . Bacteriophages as potential new therapeutics to replace or supplement antibiotics. Trends Biotechnol. 2010; 28(12):591-5. DOI: 10.1016/j.tibtech.2010.08.001. View

3.
Kim M, Bae J . Spatial disturbances in altered mucosal and luminal gut viromes of diet-induced obese mice. Environ Microbiol. 2015; 18(5):1498-510. DOI: 10.1111/1462-2920.13182. View

4.
Hagens S, Habel A, von Ahsen U, von Gabain A, Blasi U . Therapy of experimental pseudomonas infections with a nonreplicating genetically modified phage. Antimicrob Agents Chemother. 2004; 48(10):3817-22. PMC: 521880. DOI: 10.1128/AAC.48.10.3817-3822.2004. View

5.
Ormala A, Jalasvuori M . Phage therapy: Should bacterial resistance to phages be a concern, even in the long run?. Bacteriophage. 2013; 3(1):e24219. PMC: 3694056. DOI: 10.4161/bact.24219. View